MERCK & CO. INC. reported its experimental drug sacituzumab tirumotecan met primary endpoints in a late-stage trial involving 776 uterine cancer patients. The treatment outperformed standard chemotherapy by extending survival and delaying disease progression in advanced cases. Positive Phase 3 data strengthens Merck's oncology pipeline as it seeks to diversify revenue beyond its existing blockbuster treatments.
Merck uterine cancer drug meets late stage trial goals
Merck announced its drug sacituzumab tirumotecan met primary goals in a late-stage trial. The treatment helped patients live longer than those on chemotherapy.
Xurve View
Insights:
Xurve View











